Serious Adverse Effects of Extended-release Niacin/Laropiprant: Results From the Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events (HPS2-THRIVE) Trial (2019)

First Author: Haynes R
Attributed to:  Randomised trials in cardiovascular and metabolic disease funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1016/j.clinthera.2019.06.012

PubMed Identifier: 31447131

Publication URI: http://europepmc.org/abstract/MED/31447131

Type: Journal Article/Review

Parent Publication: Clinical Therapeutics

Issue: 9

ISSN: 0149-2918